Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Clin Cancer Res. 2010 Oct 1;16(19):4822-31. doi: 10.1158/1078-0432.CCR-10-1467. Epub 2010 Aug 31.
PURPOSE: To clarify and compare the antitumor effects and specific biodistribution of NK012, an SN-38-incorporating polymeric micelle, in mice bearing multiple liver metastases of human colon cancer HT-29 cells with irinotecan hydrochloride (CPT-11). EXPERIMENTAL DESIGN: The maximum tolerable dose of NK012 (30 mg/kg) or CPT-11 (66.7 mg/kg) was i.v. administered three times every 4 days to mice bearing metastases to the liver colonized 7 days after the portal administration of HT-29 cells (n = 6). In vivo antitumor effects were evaluated by bioluminescence imaging and histopathologic examination. Drug biodistribution was analyzed by high-performance liquid chromatography and fluorescence microscopy (n = 3). RESULTS: NK012 eradicated the liver metastases and produced a significant longer survival rate than CPT-11 (P = 0.0006). High-performance liquid chromatography showed the prolonged distribution of NK012 and free SN-38 released from NK012 in the tumors, liver, and spleen for weeks after NK012 administration. On the other hand, the accumulation levels of CPT-11 and free SN-38 converted from CPT-11 rapidly decreased within 1 day after CPT-11 administration. In the liver metastases, fluorescence microscopy and immunohistochemistry showed that administered NK012 was distributed mainly adjacent to tumor vessels after 1 day. As for the normal liver, NK012 was distributed in Kupffer cells instead of hepatocytes for at least 7 days after administration. CONCLUSION: This study suggests that NK012 is strongly effective against liver metastases and does not damage the liver despite the long retention time of NK012 in Kupffer cells.
目的:阐明并比较 NK012(一种含有 SN-38 的聚合物胶束)与盐酸伊立替康(CPT-11)在荷人结肠癌 HT-29 细胞多肝转移小鼠中的抗肿瘤作用和特定生物分布。
实验设计:静脉注射 NK012(30mg/kg)或 CPT-11(66.7mg/kg)的最大耐受剂量,每 4 天一次,共 3 次,于 HT-29 细胞门静脉给药后 7 天给荷转移瘤小鼠(n=6)。通过生物发光成像和组织病理学检查评估体内抗肿瘤作用。通过高效液相色谱法和荧光显微镜(n=3)分析药物生物分布。
结果:NK012 根除了肝转移,并产生了显著更长的存活率,优于 CPT-11(P=0.0006)。高效液相色谱法显示,NK012 在给药后数周内,在肿瘤、肝脏和脾脏中分布时间延长,并释放游离 SN-38。另一方面,CPT-11 和从 CPT-11 转化的游离 SN-38 的积累水平在 CPT-11 给药后 1 天内迅速下降。在肝转移瘤中,荧光显微镜和免疫组织化学显示,给药后 1 天 NK012 主要分布在肿瘤血管附近。对于正常肝脏,NK012 在给药后至少 7 天内分布在枯否细胞中,而不是肝细胞中。
结论:本研究表明,NK012 对肝转移具有很强的疗效,尽管 NK012 在枯否细胞中的滞留时间较长,但不会损害肝脏。
Int J Mol Sci. 2022-10-2
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020-3
Br J Pharmacol. 2013-6